Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2010

01-02-2010 | Translational Research and Biomarkers

Adenoviral Oncolytic Suicide Gene Therapy for a Peritoneal Dissemination Model of Gastric Cancer in Mice

Authors: Yu Imamura, MD, Shinji Ishikawa, MD, PhD, Nobutaka Sato, MD, Ryuichi Karashima, MD, Kotaro Hirashima, MD, Yukiharu Hiyoshi, MD, Youhei Nagai, MD, Yoshikatsu Koga, MD, Naoko Hayashi, MD, PhD, Masayuki Watanabe, MD, PhD, Gen Yamada, PhD, Hideo Baba, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 2/2010

Login to get access

Abstract

Background

Peritoneal dissemination of gastric cancer is often refractory to systemic therapies. Although adenoviral gene therapy has been reported to be a potentially useful therapeutic modality, the adenovirus itself has a dose-limiting toxicity. A novel system was constructed using adenoviral oncolytic suicide gene therapy targeting carcinoembryonic antigen (CEA), and its therapeutic effect and the possibility to reduce the total viral dose while still preserving the antitumor effect were assessed.

Methods

Three types of adenoviruses were prepared for this novel system: (A) Ad/CEA-Cre, (B) Ad/lox-CD::UPRT for a Cre/loxP system, and (C) Ad/CEA-E1 for conditionally replicating adenovirus. The antitumor effect of the oncolytic suicide gene therapy (A + B + C) was then evaluated in vitro. Mice bearing peritoneal dissemination of human gastric cancer were treated with either this system (A + B + C) or with a tenfold viral dose of suicide gene therapy (A + B). The adverse effects in terms of hepatotoxicity were then evaluated between the two groups.

Results

The current system (A + B + C) demonstrated significantly better cytotoxic effect for CEA-producing cell lines than did suicide gene therapy (A + B) at the same viral dose in vitro. The effect of oncolytic suicide gene therapy was almost equal to that of the tenfold viral dose of suicide gene therapy in vivo. The hepatotoxicity of the two treated groups was also found to be equivalent.

Conclusion

It was possible to reduce the total adenoviral dose of oncolytic suicide gene therapy while still preserving the antitumor effect.
Literature
1.
2.
Dupont JB, Lee JR, Burton GR, Cohn I. Adenocarcinoma of the stomach: review of 1497 cases. Cancer. 1978;41:941–7.CrossRefPubMed
3.
Yamada E, Miyaishi S, Yamauchi M, et al. The surgical treatment of cancer of the stomach. Int Surg. 1980;65:387–99.PubMed
4.
Bando E, Yonemura Y, Miwa K, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg. 1999;178:256–62.CrossRefPubMed
5.
Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol. 2006;32:602–6.CrossRefPubMed
6.
Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding. Oncology. 2000;58:96–107.CrossRefPubMed
7.
Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg. 1998;228:347–54.CrossRefPubMed
8.
Nakajima T, Nishi M, Kajitani T. Improvement in treatment results of gastric cancer with surgery and chemotherapy: experience of 9,700 cases in the Cancer Institute Hospital, Tokyo. Semin Surg Oncol. 1991;7:365–72.CrossRefPubMed
9.
Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer. 1999;86:1657–68.CrossRefPubMed
10.
Noh SH, Yoo CH, Chung HC, Roh JK, Shin DW, Min JS. (2001) Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. Oncology. 60:24–30.CrossRefPubMed
11.
Fujimura T, Yonemura Y, Shibata K, et al. Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer. Oncol Rep. 2000;7:809–14.PubMed
12.
Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–28.CrossRefPubMed
13.
Jeung HC, Rha SY, Jang WI, Noh SH, Chung HC. Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Br J Surg. 2002;89:460–6.CrossRefPubMed
14.
Takei Y, Saga Y, Mizukami H, Takayama T, Ohwada M, Ozawa K, et al. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Mol Cancer Ther. 2008;7:704–11.CrossRefPubMed
15.
Fu X, Tao L, Zhang X. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther. 2007;14:480–7.CrossRefPubMed
16.
Yu HK, Ahn JH, Lee HJ, Lee SK, Hong SW, Yoon Y, et al. Expression of human apolipoprotein(a) kringles in colon cancer cells suppresses angiogenesis-dependent tumor growth and peritoneal dissemination. J Gene Med. 2005;7:39–49.CrossRefPubMed
17.
Miura Y, Ohnami S, Aoki K, et al. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett. 2005;218:53–62.CrossRefPubMed
18.
Tanaka F, Tominaga K, Arakawa T, et al. Interleukin-10 gene transfer to peritoneal mesothelial cells suppresses peritoneal dissemination of gastric cancer cells due to a persistently high concentration in the peritoneal cavity. Cancer Gene Ther. 2008;15:51–9.CrossRefPubMed
19.
Miyagi M, Aoyagi K, Kato S, Shirouzu K. The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol. 2007;12:17–24.CrossRefPubMed
20.
Tsunemitsu Y, Kagawa S, Fujiwara T, et al. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut. 2004;53:554–60.CrossRefPubMed
21.
Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 1999;6:113–38.CrossRefPubMed
22.
Lan KH, Kanai F, Omata M, et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. 1997;57:4279–84.PubMed
23.
Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Yamaue H, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the Cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 2001;61:6158–62.PubMed
24.
Kijima T, Osaki T, Kishimoto T, et al. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res. 1999;59:4906–11.PubMed
25.
Goto H, Osaki T, Hayashi S, et al. Gene therapy utilizing the Cre/loxP system selectively suppresses tumor growth of disseminated carcinoembryonic antigen-producing cancer cells. Int J Cancer. 2001;94:414–9.CrossRefPubMed
26.
Nishiyama T, Kawamura Y, Sakai T, et al. Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res. 1985;45:1753–61.PubMed
27.
Chung-Faye GA, Chen MJ, Kerr DJ, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001;8:1547–54.CrossRefPubMed
28.
Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999;59:2623–8.PubMed
29.
Sato Y, Tanaka K, Saito I, et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem Biophys Res Commun. 1998;244:455–62.CrossRefPubMed
30.
Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002;9:979–86.CrossRefPubMed
31.
Small EJ, Carducci MA, Wilding G, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14:107–17.CrossRefPubMed
32.
Tanaka T, Huang J, Hamada H, et al. Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res. 2006;12:3803–13.CrossRefPubMed
33.
Akbulut H, Zhang L, Tang Y, Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther. 2003;10:388–95.CrossRefPubMed
34.
Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, et al. Sectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology. 2003;125:1203–18.CrossRefPubMed
35.
Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing effect of cancer cells by herpes simplex virus thymidine kinase gene is mediated by conneins. Proc Natl Acad Sci USA. 1996;93:1831–5.CrossRefPubMed
36.
Matono S, Tanaka T, Sueyoshi S, Yamana H, Fujita H, Shirouzu K. Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer. Int J Oncol. 2003;23:1309–15.PubMed
37.
Erbs P, Regulier E, Mehtali M, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000;60:3813–22.PubMed
38.
Tomko R, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroups C adenoviruses and subgroup B coxackieviruses. Proc Natl Acad Sci USA. 1997;94:3352–6.CrossRefPubMed
39.
Miyagawa K, Sakakura C, Otsuji E, et al. Overexpression of RegIV in peritoneal dissemination of gastric cancer and its potential as A novel marker for the detection of peritoneal micrometastasis. Anticancer Res. 2008;28:1169–79.PubMed
40.
Goldenberg DM, Sharkey RM, Primus FJ. Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections. J Natl Cancer Inst. 1976;57:11–22.PubMed
41.
Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. Cancer. 2007;109:188–97.CrossRefPubMed
42.
Heideman DA, Snijders PJ, Gerritsen WR, et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAMtargeted adenoviral vectors. Cancer Gene Ther. 2001;8:342–51.CrossRefPubMed
Metadata
Title
Adenoviral Oncolytic Suicide Gene Therapy for a Peritoneal Dissemination Model of Gastric Cancer in Mice
Authors
Yu Imamura, MD
Shinji Ishikawa, MD, PhD
Nobutaka Sato, MD
Ryuichi Karashima, MD
Kotaro Hirashima, MD
Yukiharu Hiyoshi, MD
Youhei Nagai, MD
Yoshikatsu Koga, MD
Naoko Hayashi, MD, PhD
Masayuki Watanabe, MD, PhD
Gen Yamada, PhD
Hideo Baba, MD, PhD, FACS
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0852-3

Other articles of this Issue 2/2010

Annals of Surgical Oncology 2/2010 Go to the issue

Translational Research and Biomarkers

Glucose-Regulated Protein 78 Is a Novel Contributor to Acquisition of Resistance to Sorafenib in Hepatocellular Carcinoma

Endocrine Tumors

Controversies in Thyroid Pathology: Thyroid Capsule Invasion and Extrathyroidal Extension

Translational Research and Biomarkers

p53 Genotype Predicts Response to Chemotherapy in Patients with Squamous Cell Carcinoma of the Esophagus

Colorectal Cancer

Impact of Palliative Chemotherapy and Surgery on Management of Stage IV Incurable Colorectal Cancer

Pancreatic Tumors

Preoperative Diabetes Mellitus and Long-Term Survival After Resection of Pancreatic Adenocarcinoma

Melanomas

Outcome of Patients with a Positive Sentinel Lymph Node who do not Undergo Completion Lymphadenectomy